453 related articles for article (PubMed ID: 19365035)
1. Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye.
Hongyok T; Chae JJ; Shin YJ; Na D; Li L; Chuck RS
Arch Ophthalmol; 2009 Apr; 127(4):525-32. PubMed ID: 19365035
[TBL] [Abstract][Full Text] [Related]
2. Topical steroid and non-steroidal anti-inflammatory drugs inhibit inflammatory cytokine expression on the ocular surface in the botulinum toxin B-induced murine dry eye model.
Zhu L; Zhang C; Chuck RS
Mol Vis; 2012; 18():1803-12. PubMed ID: 22815633
[TBL] [Abstract][Full Text] [Related]
3. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model.
Park CY; Zhuang W; Lekhanont K; Zhang C; Cano M; Lee WS; Gehlbach PL; Chuck RS
Mol Vis; 2007 Nov; 13():2222-32. PubMed ID: 18087241
[TBL] [Abstract][Full Text] [Related]
4. Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulinum toxin B-induced mouse model.
Lekhanont K; Leyngold IM; Suwan-Apichon O; Rangsin R; Chuck RS
Cornea; 2007 Jan; 26(1):84-9. PubMed ID: 17198019
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye.
Li Z; Woo JM; Chung SW; Kwon MY; Choi JS; Oh HJ; Yoon KC
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):155-62. PubMed ID: 23211823
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model.
Zhu L; Shen J; Zhang C; Park CY; Kohanim S; Yew M; Parker JS; Chuck RS
Mol Vis; 2009; 15():250-8. PubMed ID: 19190733
[TBL] [Abstract][Full Text] [Related]
7. Effect of 0.025% FK-506 eyedrops on botulinum toxin B-induced mouse dry eye.
Lin BW; Chen MZ; Fan SX; Chuck RS; Zhou SY
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):45-53. PubMed ID: 25491293
[TBL] [Abstract][Full Text] [Related]
8. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Lekhanont K; Park CY; Smith JA; Combs JC; Preechawat P; Suwan-Apichon O; Rangsin R; Chuck RS
J Ocul Pharmacol Ther; 2007 Feb; 23(1):27-34. PubMed ID: 17341147
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic effects of Pyranoprofen on the mouse dry eye induced by topical medication of Benzalkonium Chloride].
He H; Liu ZG; Lin ZR; Liu XC; He H; Xiao QG
Zhonghua Yan Ke Za Zhi; 2012 Jan; 48(1):33-40. PubMed ID: 22490914
[TBL] [Abstract][Full Text] [Related]
10. Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease.
Ecoiffier T; El Annan J; Rashid S; Schaumberg D; Dana R
Arch Ophthalmol; 2008 Dec; 126(12):1695-9. PubMed ID: 19064851
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 receptor-1-deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye.
Narayanan S; Corrales RM; Farley W; McDermott AM; Pflugfelder SC
Cornea; 2008 Aug; 27(7):811-7. PubMed ID: 18650668
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of topical infliximab in a mouse model of experimental dry eye.
Li Z; Choi W; Oh HJ; Yoon KC
Cornea; 2012 Nov; 31 Suppl 1():S25-31. PubMed ID: 23038030
[TBL] [Abstract][Full Text] [Related]
13. Effects of Topical Mucolytic Agents on the Tears and Ocular Surface: A Plausible Animal Model of Mucin-Deficient Dry Eye.
Li X; Kang B; Woo IH; Eom Y; Lee HK; Kim HM; Song JS
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3104-3114. PubMed ID: 30025127
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 0.025% FK-506, 0.05% Cyclosporin A, and 0.3% Sodium Hyaluronate Eye Drops for the Treatment of Botulinum Toxin B-Induced Mouse Dry Eye.
Lin BW; Huang WL; Wang L; Chen ZM
J Ocul Pharmacol Ther; 2018 Nov; 34(9):633-641. PubMed ID: 30227093
[TBL] [Abstract][Full Text] [Related]
15. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye.
Lekhanont K; Park CY; Combs JC; Suwan-Apichon O; Rangsin R; Chuck RS
J Ocul Pharmacol Ther; 2007 Feb; 23(1):83-8. PubMed ID: 17341156
[TBL] [Abstract][Full Text] [Related]
16. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface.
Luo L; Li DQ; Doshi A; Farley W; Corrales RM; Pflugfelder SC
Invest Ophthalmol Vis Sci; 2004 Dec; 45(12):4293-301. PubMed ID: 15557435
[TBL] [Abstract][Full Text] [Related]
17. Topical omega-3 and omega-6 fatty acids for treatment of dry eye.
Rashid S; Jin Y; Ecoiffier T; Barabino S; Schaumberg DA; Dana MR
Arch Ophthalmol; 2008 Feb; 126(2):219-25. PubMed ID: 18268213
[TBL] [Abstract][Full Text] [Related]
18. Antioxidant and inflammatory cytokine in tears of patients with dry eye syndrome treated with preservative-free versus preserved eye drops.
Jee D; Park SH; Kim MS; Kim EC
Invest Ophthalmol Vis Sci; 2014 Jul; 55(8):5081-9. PubMed ID: 24994869
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Suwan-apichon O; Rizen M; Rangsin R; Herretes S; Reyes JM; Lekhanont K; Chuck RS
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):133-9. PubMed ID: 16384954
[TBL] [Abstract][Full Text] [Related]
20. Effects of eye drops containing a mixture of omega-3 essential fatty acids and hyaluronic acid on the ocular surface in desiccating stress-induced murine dry eye.
Li Z; Choi JH; Oh HJ; Park SH; Lee JB; Yoon KC
Curr Eye Res; 2014 Sep; 39(9):871-8. PubMed ID: 24559509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
